首页> 外文OA文献 >4CPS-071 Analysis of effectiveness: use of pertuzumab and trastuzumab in neoadjuvant treatment in patients with HER2 positive breast cancer and its correlation with plasma levels of trastuzumab

【2h】

4CPS-071 Analysis of effectiveness: use of pertuzumab and trastuzumab in neoadjuvant treatment in patients with HER2 positive breast cancer and its correlation with plasma levels of trastuzumab

机译：4CPS-071效果分析：使用Pertuzumab和Trastuzumab在HER2阳性乳腺癌患者中的新辅助治疗及其与血浆水平的相关性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
R Álvarez Ambite; F Gutierrez Nicolas; I Ceballos Lezna; IJ Expósito Afonso; J González García; R Ramos Díaz; J Cruz Jurado; GJ Nazco Casariego;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. HER2 Type Male Breast Cancer Successfully Treated with Pertuzumab, Trastuzumab, and Eribulin Therapy: A Case Report [J] . Masahiro Kitada, Shunsuke Yasuda, Masahiro Abe, 癌症治疗（英文） . 2020,第003期
2. COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN [J] . Colomer R., Ciruelos E., De la Haba J., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：HER2 +乳腺癌患者对Pertuzubab，曲妥珠单抗和多西他赛进行新辅助化疗的费用效用分析
3. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [J] . Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, Breast Cancer Research . 2017,第1期

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗，曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛，帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌的新辅助治疗
4. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J] . Hurvitz Sara A., Martin Miguel, Symmans W. Fraser, The lancet oncology . 2018,第1期

机译：Neoadjuvant Trastuzumab，Pertuzumab和化疗与Her2阳性乳腺癌（Kristine）的患者患有Trastuzumab Emtansine Plus Pertuzumab：随机，开放标签，多期，第3阶段试验
5. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
6. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
7. Biomarker analysis of the NeoSphere study: pertuzumab trastuzumab and docetaxel versus trastuzumab plus docetaxel pertuzumab plus trastuzumab or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [O] . Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, 2017

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌的新辅助治疗
8. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [O] . 2017

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗，曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛，帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛对HER2阳性乳腺癌的新辅助治疗

4CPS-071 Analysis of effectiveness: use of pertuzumab and trastuzumab in neoadjuvant treatment in patients with HER2 positive breast cancer and its correlation with plasma levels of trastuzumab

著录项

相似文献

相关主题

期刊订阅